AzTrials
AzTrials

Dental CariesDentalCariesNCT07609797

The Effects of Sodium Fluoride and Chlorhexidine Use on Salivary IL-6 and Matrix Metalloproteinase Levels in Children With Active Caries

A study testing 5% Sodium Fluoride Varnish, 2% Chlorhexidine Pre-Treatment + 5% NaF Varnish and Standard Oral Hygiene Education in people with Dental Caries and Dental Caries in Children, run by Gül Keskin at 1 site in Turkey (Türkiye).

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to compare salivary IL-6, MMP-8, MMP-9, and TIMP-1 levels between healthy children and caries-active children, and to evaluate the effects of 5% sodium fluoride (NaF) varnish and 2% chlorhexidine (CHX) used in caries prevention on these biomarkers. Read more about this study

Who is it for?
Ages 6 to 8 yearsHealthy volunteers can take part
Conditions the study is for
Dental Caries, Dental Caries in Children
What is being tested?
5% Sodium Fluoride Varnish, 2% Chlorhexidine Pre-Treatment + 5% NaF Varnish and Standard Oral Hygiene Education
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteTurkey (Türkiye)
Study dates
15 May 2026to 30 Jun 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 8 years
  • All sexes
  • Healthy volunteers accepted
  • Child

Who may be able to join

  • Children aged 6-8 years with all first permanent molars erupted
  • For active caries groups (Groups A, B, C): participants must meet at least one of the following criteria: dmft ≥ 6, or presence of at least one active caries lesion with an ICDAS code ≥ 3, or clinical evidence of active caries on ≥ 10 surfaces
  • For the dmft = 0 reference group (Group D): all surfaces caries-free and non-high-risk individuals (ICDAS II = 0); only baseline (T0) saliva sampling will be performed
  • No professional topical fluoride application or continuous CHX use within the past 3 months
  • No systemic chronic disease, immunodeficiency, or severe neuromotor disorder
  • No gingival redness, swelling, or bleeding
  • Written parental informed consent obtained

Who cannot join

  • Known allergy to fluoride compounds or varnish components
  • Behavioral problems that would prevent safe cooperation during application
  • Regular antibiotic use within the past 1 month
  • Individuals with infectious diseases
  • Those at high risk of endocarditis
  • History of substance dependence
  • Epilepsy
  • Renal failure or immunosuppression

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

GÜL KESKİN, DDS, PhD contact

905444468857

gul.keskin@alanya.edu.tr

BİNNUR B ÖZDEMİR, DDS contact

905069033834

busra.ozdemir@alanya.edu.tr

Turkey (Türkiye)1 site, 1 recruiting
  • Alanya Alaaddin Keykubat University, Faculty of Dentistry

    Alanya, Antalya, 07450

    GÜL KESKİN, DDS, PhD, 905444468857, gul.keskin@alanya.edu.tr

    BİNNUR B ÖZDEMİR, DDS, 905069033834, busra.ozdemir@alanya.edu.tr

    Recruiting

Other trials in Turkey (Türkiye)

About this study

This study aims to compare salivary IL-6, MMP-8, MMP-9, and TIMP-1 levels between healthy children and caries-active children, and to evaluate the effects of 5% sodium fluoride (NaF) varnish and 2% chlorhexidine (CHX) used in caries prevention on these biomarkers.

The study will be conducted at Alanya Alaaddin Keykubat University, Faculty of Dentistry, Department of Pediatric Dentistry. Informed consent will be obtained from children and their parents/guardians. Investigator calibration will be performed using Cohen's kappa method prior to data collection. Sample size was calculated assuming 80% power (1-β = 0.80), α = 0.05, and Cohen's d ≈ 0.8, resulting in 20 participants per group using G*Power 3.1 software.

Read more

Study groups: Group A: 5% NaF varnish. Group B: 2% CHX + 5% NaF varnish. Group C: Standard oral hygiene education (negative control). Group D: Caries-free children (biological reference; baseline saliva sampling only).

Saliva samples will be collected at T0 (baseline), T1 (30 minutes post-application), and T2 (1 month). Unstimulated whole saliva will be collected, centrifuged at 5,000 g for 10 minutes at 4°C, and stored at -80°C. IL-6, MMP-8, MMP-9, and TIMP-1 levels will be measured using CE-marked/FDA-approved human saliva ELISA kits.

Read the detailed description

Biomarkers to Be Measured in the Study and Expected Benefits:Biomarkers to Be Measured in the Study and Expected Benefits:

Dental caries is a multifactorial infectious disease with high prevalence that affects a large proportion of the world's population. The fundamental pathogenesis of the disease is characterized by tissue destruction caused by complex and synergistic biological processes that arise from the interaction of acids-produced through the fermentation of dietary carbohydrates by bacteria-with susceptible host factors such as dental hard tissues and saliva. The body develops an inflammatory response against dental caries, which is characterized by infection and tissue destruction; the purpose of this response is to eliminate the agent that initiated the inflammation and to restore tissue homeostasis.

As a result of bacterial stimulation and recognition, odontoblasts, pulp tissue fibroblasts, and immune cells such as dendritic cells, macrophages, and neutrophils collectively produce a large number of molecules; these include cytokines and chemokines such as interleukin-1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), and prostaglandins, which prolong the inflammatory state and thereby support the activation of innate and adaptive immune responses.

IL-6, produced by odontoblasts and immune cells, increases markedly in the inflamed pulp. IL-6 neutralizes bacterial cell wall components by enhancing the secretion of LBP (lipopolysaccharide-binding protein) and regulates the immune response by reducing pro-inflammatory cytokine production. It also contributes to edema formation by increasing vascular permeability. It has been reported that salivary IL-6 may serve as a potential biomarker for assessing caries severity.

As caries lesions progress toward the pulp, demineralization and collagen degradation in the dentin matrix accelerate. The decrease in pH exposes collagen fibers to proteolytic enzymes, facilitating the demineralization of the dentin matrix. This acidic environment also accelerates caries progression by increasing the activation of MMPs (zinc- and calcium-dependent endopeptidases). MMPs are classified into five subgroups based on their substrate specificity and structural similarities: collagenases, stromelysins, gelatinases, matrilysins, and membrane-type MMPs. These enzymes can be activated in an acidic environment or by lactate released by cariogenic bacteria. MMP-8 (neutrophil collagenase) can cleave triple-helical fibrillar collagens into characteristic 3/4 and 1/4 fragments. MMP-9 is a gelatinase capable of degrading type IV collagen. The activation of MMP-8 and MMP-9 plays a critical role in collagen degradation in dentin caries lesions.

The activity of MMPs, which play a central role in dentin collagen degradation, also stands out as an important target for maintaining tissue balance. The control of these enzymes is primarily achieved through tissue inhibitors of metalloproteinases (TIMPs). TIMP-1 and TIMP-2 are the primary regulators of MMP activity and effectively prevent excessive extracellular matrix (ECM) degradation . TIMP-2 exhibits strong inhibition of polymorphonuclear cell (PMN)-derived MMPs, while TIMP-1 demonstrates more pronounced inhibition of fibroblast-derived MMPs.

Inhibition of MMP activity is considered a potential strategy for slowing caries progression and preventing dentin erosion. In this context, sodium fluoride (NaF) and chlorhexidine (CHX) are cited in the literature as the principal agents capable of reducing MMP activity. NaF has been shown to inhibit the catalytic activity of recombinant MMP-8 and MMP-9. Similarly, CHX can largely prevent collagen degradation in demineralized dentin and can demonstrate long-lasting anti-MMP effects by binding electrostatically to the dentin matrix.

All of these findings demonstrate that inflammation can be objectively measured through both local and systemic biomarkers. The dynamic interaction between pro-inflammatory signals and matrix degradation, along with the endogenous inhibitors involved in this process, is of critical importance for the preservation of dentin tissue and the control of caries progression. However, studies that comprehensively reveal the molecular-level interactions of this axis, particularly in caries-active children, are limited in the literature. In this context, the aim of our study is to compare the biomarkers IL-6, MMP-8, MMP-9, and TIMP-1-representing the key components of the inflammation-matrix degradation axis-between healthy children and caries-active children, and to evaluate the effects of materials such as NaF and CHX used in caries prevention on these parameters.

Biomarker Analysis The levels of IL-6, MMP-8, MMP-9, and TIMP-1 in saliva samples will be evaluated using human saliva enzyme-linked immunosorbent assay (ELISA) kits. Biomarker analyses (ELISA) of the samples will be performed at the ALKU Faculty of Medicine Pharmacology Laboratory.

The obtained data will be statistically analyzed. Descriptive statistics: Quantitative variables will be expressed as mean ± standard deviation or median and interquartile range (IQR), and qualitative variables will be expressed as frequencies and percentages.

Between-group comparisons and within-group changes over time will be evaluated using appropriate parametric or non-parametric tests.

Results will be interpreted by correlating changes in salivary biomarker levels with clinical findings.

Being tested
5% Sodium Fluoride Varnish, 2% Chlorhexidine Pre-Treatment + 5% NaF Varnish, Standard Oral Hygiene Education
Keywords
Dental caries, Matrix metalloproteinase, Interleukin-6, Sodium fluoride, Chlorhexidine
Medical subject headings
Dental Caries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 5% Sodium Fluoride VarnishOther

    Teeth are gently air-dried for 30 seconds under isolation with cotton rolls and aspirator. Approximately 0.5 mL of 5% NaF varnish is applied to all tooth surfaces sequentially by quadrant starting from the upper jaw using an applicator tip and left in place for 1 minute. Parents are instructed to restrict water and hard food intake for 1 hour post-application. This is a routine preventive application; no off-label use is involved.

  • 2% Chlorhexidine Pre-Treatment + 5% NaF VarnishOther

    Following isolation and air-drying, 2% chlorhexidine solution is applied to the lesion/tooth surfaces using an applicator tip and left in place for 30 seconds. Excess CHX is then absorbed. Precautions are taken to prevent ingestion. This pre-treatment is performed immediately prior to 5% NaF varnish application. This is a routine preventive application; no off-label use is involved.

  • Standard Oral Hygiene EducationBehavioural

    Children and parents receive standardized oral hygiene education including instruction on twice-daily brushing with fluoride toothpaste, reduction of sugar intake frequency, and a brief parent information brochure. No professional topical agent is applied. Necessary treatment will be offered at the end of the study upon request (wait-list design).

Study groups in NCT07609797
Study groupRoleWhat they receive
5% Sodium Fluoride (NaF) VarnishExperimentalCaries-active children aged 6-8 years. Teeth are gently air-dried for 30 seconds under isolation with cotton rolls and aspirator. Approximately 0.5 mL of 5% NaF varnish is applied to all teeth sequentially by quadrant starting from the upper jaw using an applicator tip and left in place for 1 minute. Parents are instructed to restrict water and hard food intake for 1 hour post-application. Saliva samples collected at T0, T1 and T2. n=20.
Receives: Other: 5% Sodium Fluoride Varnish
2% Chlorhexidine Pre-Treatment + 5% NaF VarnishExperimentalCaries-active children aged 6-8 years. Teeth are gently air-dried for 30 seconds under isolation. 2% CHX is applied to the lesion/tooth surfaces using an applicator tip and left for 30 seconds. Excess CHX is absorbed, an additional 30 seconds was allowed to pass.NaF varnish was then applied and left for 1 minute. Precautions are taken to prevent CHX ingestion. Parents are instructed to restrict water and hard food intake for 1 hour post-application. Saliva samples collected at T0, T1 and T2. n=20.
Receives: Other: 2% Chlorhexidine Pre-Treatment + 5% NaF Varnish
Standard Care / Oral Hygiene EducationActive comparatorCaries-active children aged 6-8 years. No professional topical agent is applied. Children and parents receive standardized oral hygiene education including twice-daily brushing with fluoride toothpaste, reduction of sugar frequency, and a brief parent information brochure. Necessary treatment will be offered at the end of the study upon request (wait-list design). Saliva samples collected at T0 and T2. n=20.
Receives: Behavioral: Standard Oral Hygiene Education
Caries-Free Healthy ControlNo interventionAge- and sex-matched caries-free children (ICDAS II = 0, dmft = 0) aged 6-8 years. No intervention is applied. Clinical assessment (dmft/ICDAS) is performed and recorded. Saliva sampling is performed at T0 only. This group serves as a non-randomized biological reference group. n=20.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Salivary MMP-8 Levels

    Change in salivary matrix metalloproteinase-8 (MMP-8) concentration measured by ELISA from baseline (T0) to post-application (T1) and 1 month post-intervention (T2) , and comparison between caries-active and caries-free groups at baseline. Unstimulated whole saliva samples will be analyzed using CE-marked/FDA-approved human saliva ELISA kits. Results expressed as ng/mL.

    Measured: Baseline (T0), 30 minutes post-application (T1), 1 month post-intervention (T2)

  2. Change in Salivary IL-6 Levels

    Change in salivary interleukin-6 (IL-6) concentration measured by ELISA from baseline (T0) to post-application (T1) and 1 month post-intervention (T2) , and comparison between caries-active and caries-free groups at baseline. Unstimulated whole saliva samples will be collected, centrifuged at 5,000 g for 10 minutes at 4°C, stored at -80°C, and analyzed using CE-marked/FDA-approved human saliva ELISA kits. Results expressed as pg/mL.

    Measured: Baseline (T0), 30 minutes post-application (T1), 1 month post-intervention (T2)

  3. Change in Salivary MMP-9 Levels

    Change in salivary matrix metalloproteinase-9 (MMP-9) concentration measured by ELISA from baseline (T0) to post-application (T1) and 1 month post-intervention (T2), and comparison between caries-active and caries-free groups at baseline. Unstimulated whole saliva samples will be analyzed using CE-marked/FDA-approved human saliva ELISA kits. Results expressed as ng/mL.

    Measured: Baseline (T0), 30 minutes post-application (T1), 1 month post-intervention (T2)

  4. Change in Salivary TIMP-1 Levels

    Change in salivary tissue inhibitor of metalloproteinase-1 (TIMP-1) concentration measured by ELISA from baseline (T0) to post-application (T1) and 1 month post-intervention (T2), and comparison between caries-active and caries-free groups at baseline. Unstimulated whole saliva samples will be analyzed using CE-marked/FDA-approved human saliva ELISA kits. Results expressed as ng/mL.

    Measured: Baseline (T0), 30 minutes post-application (T1), 1 month post-intervention (T2)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 May 2026
  2. Study start15 May 2026
  3. Primary completion1 Jan 2027 (estimated)
  4. Study completion30 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
This is a single-center, parallel-group, randomized controlled, open-label clinical study. Biomarker measurements will be evaluated objectively. Blinding of the application is not practically feasible due to the nature of the procedures. Additionally, a non-randomized reference group consisting of healthy individuals with dmft = 0 will be included in the study for comparison purposes. Children with active caries participating in the study have been randomized with equal probability into three intervention groups (5% NaF, 2% CHX + 5% NaF, Negative control). Randomization was performed using computer-assisted random methods to prevent selection bias. The healthy, caries-free control group (Group D) was selected on a non-randomized basis.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07609797
Sponsor's protocol ID
2025-KAEK-44
Acronym
DentalCaries
Status last verified
May 2026
First submitted
20 May 2026
Last updated
2 Jun 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Individual participant data will not be shared with external researchers. The informed consent form explicitly states that all personal data will be kept confidential, participant identities will be stored using coded numbers, and data will not be disclosed to third parties. As participants are children aged 6-8 years, additional data protection considerations apply.

Questions about this trial

What is this clinical trial studying?

A study testing 5% Sodium Fluoride Varnish, 2% Chlorhexidine Pre-Treatment + 5% NaF Varnish and Standard Oral Hygiene Education in people with Dental Caries and Dental Caries in Children, run by Gül Keskin at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact GÜL KESKİN, DDS, PhD (905444468857, gul.keskin@alanya.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Salivary MMP-8 Levels (time frame: Baseline (T0), 30 minutes post-application (T1), 1 month post-intervention (T2)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in